Adaptive Natural Killer Cells Facilitate Effector Functions of Daratumumab in Multiple Myeloma.
Hyunsoo ChoKyung Hwan KimHoyoung LeeChang Gon KimHaerim ChungYoon Seok ChoiSu-Hyung ParkJune-Won CheongYoo Hong MinEui-Cheol ShinJin Seok KimPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Our findings indicate that adaptive NK cells are an important mediator of ADCC in multiple myeloma and support direct future efforts to better predict and improve the treatment outcome of daratumumab by selectively employing adaptive NK cells.